208 related articles for article (PubMed ID: 33277846)
1. ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6).
Duan L; Yan Y; Wang G; Xing YL; Sun J; Wang LL
J BUON; 2020; 25(5):2279-2286. PubMed ID: 33277846
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6.
Liang M; Li Q; Shi S; Tian YN; Feng Y; Yang Y; Dong M; Zhang J; He J
Gynecol Obstet Invest; 2021; 86(6):533-541. PubMed ID: 34818258
[TBL] [Abstract][Full Text] [Related]
3. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of CDK6 expression by microRNA-126-5p and its influence on the proliferation and invasion of esophageal cancer cells.
Gu JF; Liu SG; Pan Q; Qin F; Li YY
Anat Rec (Hoboken); 2020 Nov; 303(11):2811-2820. PubMed ID: 31916689
[TBL] [Abstract][Full Text] [Related]
5. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
6. MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer.
Li B; Xu X; Zheng L; Jiang X; Lin J; Zhang G
Mol Biol Rep; 2023 Aug; 50(8):6819-6827. PubMed ID: 37392283
[TBL] [Abstract][Full Text] [Related]
7. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
8. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
9. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
10. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
11. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
Chen Y; Wang L; Zhou J
J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
[TBL] [Abstract][Full Text] [Related]
12. Circ_0058063 regulates CDK6 to promote bladder cancer progression by sponging miR-145-5p.
Sun M; Zhao W; Chen Z; Li M; Li S; Wu B; Bu R
J Cell Physiol; 2019 Apr; 234(4):4812-4824. PubMed ID: 30362519
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6.
Cao J; Zhang Y; Mu J; Yang D; Gu X; Zhang J
Hum Cell; 2021 Jul; 34(4):1185-1196. PubMed ID: 33813728
[TBL] [Abstract][Full Text] [Related]
14. [miRNA-191-5p represses cell growth by targeting CDK6 in gastric cancer].
Cao NJ; Hou HH; Li F; Guo ST; Wang Y
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(46):3689-3693. PubMed ID: 33342146
[No Abstract] [Full Text] [Related]
15. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
16. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
17. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J
Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231
[TBL] [Abstract][Full Text] [Related]
18. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
[TBL] [Abstract][Full Text] [Related]
20. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
